Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Inventiva S.A. was the subject of an amended beneficial-ownership report in which BioDiscovery 6 FPCI, Andera Partners, Stephane Bergez and Francois Xavier Mauron each reported beneficial ownership of 15,929,476 ordinary shares, or 6.7%, as of September 30, 2026. Each listed the same amount as shared voting and shared dispositive power.
BioDiscovery 6 FPCI is the record holder of 12,296,295 ordinary shares and 3,633,181 American Depositary Shares, each representing one ordinary share. Andera Partners makes voting and disposition decisions for BioDiscovery 6 FPCI; Bergez and Mauron are Andera Partners’ managing partners. The reporting persons expressly disclaim that they are a group. The reported percentage is based on 237,986,695 ordinary shares outstanding as of September 30, 2026.
Key Figures
Beneficial ownership:15,929,476 ordinary sharesPercent of class:6.7%Ordinary shares held of record:12,296,295 shares+2 more
5 metrics
Beneficial ownership15,929,476 ordinary sharesReported by each reporting person as of September 30, 2026
Percent of class6.7%Reported by each reporting person as of September 30, 2026
Ordinary shares held of record12,296,295 sharesHeld by BioDiscovery 6 FPCI
American Depositary Shares3,633,181 ADSHeld by BioDiscovery 6 FPCI; each ADS represents one ordinary share
Ordinary shares outstanding237,986,695 sharesAs of September 30, 2026, as reported by Inventiva S.A.
"may be deemed to beneficially own the securities held by BioDiscovery 6"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Shared Voting Powerfinancial
"Shared Voting Power 15,929,476.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Powerfinancial
"Shared Dispositive Power 15,929,476.00"
American Depositary Sharesfinancial
"3,633,181 American Depositary Shares ("ADS")"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Inventiva (IVA) shares did the reporting persons beneficially own?
Each of the four reporting persons reported beneficial ownership of 15,929,476 ordinary shares, or 6.7% of the class, as of September 30, 2026. The position comprises 12,296,295 ordinary shares and 3,633,181 American Depositary Shares, each representing one ordinary share.
Who holds and makes decisions about the Inventiva (IVA) shares?
BioDiscovery 6 FPCI is the record holder of 12,296,295 ordinary shares and 3,633,181 American Depositary Shares. Andera Partners makes voting and disposition decisions for BioDiscovery 6 FPCI; Stephane Bergez and Francois Xavier Mauron are Andera Partners’ managing partners.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
INVENTIVA S.A.
(Name of Issuer)
Ordinary Shares, nominal value Euro 0.01 per share
(Title of Class of Securities)
46124U107
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
46124U107
1
Names of Reporting Persons
Andera Partners
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
15,929,476.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
15,929,476.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
15,929,476.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
46124U107
1
Names of Reporting Persons
BioDiscovery 6 FPCI
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
15,929,476.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
15,929,476.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
15,929,476.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
46124U107
1
Names of Reporting Persons
Stephane Bergez
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
15,929,476.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
15,929,476.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
15,929,476.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
46124U107
1
Names of Reporting Persons
Francois Xavier Mauron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
15,929,476.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
15,929,476.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
15,929,476.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
INVENTIVA S.A.
(b)
Address of issuer's principal executive offices:
50 rue de Dijon, Daix, I0, 21121 .
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
BioDiscovery 6 FPCI ("BioDiscovery 6")
Andera Partners ("Andera")
Stephane Bergez ("Bergez")
Francois Xavier Mauron ("Mauron")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A.
(b)
Address or principal business office or, if none, residence:
2 place de Rio de Janeiro
75008 Paris
France
(c)
Citizenship:
BioDiscovery 6 France
Andera France
Bergez France
Mauron France
(d)
Title of class of securities:
Ordinary Shares, nominal value Euro 0.01 per share
(e)
CUSIP No.:
46124U107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of ordinary shares of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
BioDiscovery 6 is the record holder of (i) 12,296,295 ordinary shares and (ii) 3,633,181 American Depositary Shares ("ADS") of the Issuer, representing an aggregate of 3,633,181 ordinary shares. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6.
CUSIP Number 46124U107 has been assigned to the ADS of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents one ordinary share of the Issuer. No CUSIP has been assigned to the Issuer's ordinary shares.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentage of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 237,986,695 ordinary shares outstanding as of September 30, 2026, as reported by the Issuer.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Andera Partners
Signature:
/s/ Stephane Bergez
Name/Title:
By Stephane Bergez, Managing Partner
Date:
10/27/2026
BioDiscovery 6 FPCI
Signature:
/s/ Stephane Bergez
Name/Title:
By Andera Partners, its management company, By Stephane Bergez, Managing Partner
Date:
10/27/2026
Stephane Bergez
Signature:
/s/ Stephane Bergez
Name/Title:
Stephane Bergez
Date:
10/27/2026
Francois Xavier Mauron
Signature:
/s/ Francois Xavier Mauron
Name/Title:
Francois Xavier Mauron
Date:
10/27/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the SEC on April 14, 2025).
